Eli Lilly's tirzepatide is off the FDA's shortage list: What it means for patients
Eli Lilly's weight-loss drug is no longer on the Food and Drug Administration's drug shortage list. Compounding pharmacies ...
FDA Says Compounding Pharmacies Can Keep Making Weight-Loss Med Tirzepatide, for Now
TUESDAY, Oct. 15, 2024 (HealthDay News) -- Pharmacists may continue making compounded versions of the weight-loss medication ...
ENDPOINTS NEWS9 小时
FDA won't take ac­tion against GLP-1 com­pounders as it re­thinks tirzepatide short­age
The FDA clarified Thursday that it won't take action against GLP-1 compounders for certain violations while it reevaluates ...
Compounding pharmacies can resume making tirzepatide as FDA reconsiders shortage
The FDA said in a court filing late Friday that it would allow pharmacists to continue making compounded versions of ...
Sagimet Soars: FDA Breakthrough Therapy Designation And Lancet Review Validate Denifanstat
Discover why Sagimet Biosciences' Denifanstat is a top contender in treating MASH, with FDA designation and strong financials ...
Health on MSN2 天
What the End of a Tirzepatide Shortage Would Mean for Access to Compounded Weight Loss Drugs
In response to a lawsuit, the FDA has said that it will reevaluate its previous decision to remove tirzepatide from its ...
腾讯网3 天
FDA“三思“将礼来(LLY.US)减肥神药移除短缺名单，Hims & Hers Health(HIMS.US ...
智通财经APP获悉，在美国食品药品监督管理局(FDA)决定将礼来公司(LLY.US)的替西帕肽(Tirzepatide)从药品短缺清单中移除后，一起针对此次除名举措的诉讼引发了Hims & Hers Health(HIMS.US)周一交易上涨，收涨9 ...
腾讯网6 天
美国肥胖群体的福音：FDA考虑允许复配版礼来(LLY.US)减肥药
智通财经APP获悉，美国食品和药物管理局(FDA)在周五同意重新考虑上个月所作出的决定，即禁止私人的药物配制商销售他们自己复合制作版本的礼来公司(LLY.US)减肥以及治疗糖尿病药物。该机构在一份法庭文件中表示，现在将考虑允许复配药房和药物基础设施继 ...
FiercePharma4 天
In win for compounders, FDA will review its decision to put Eli Lilly's tirzepatide on ...
In accepting the FDA’s motion, U.S. District Judge Mark Pittman put on hold a lawsuit filed by the Outsourcing Facilities ...
BofA上调Hims and Hers目标价，因FDA药品更新
BofA Securities调整了对Hims and Hers (NYSE:HIMS)的展望，将目标价从20.00美元上调至23.00美元，并维持买入评级。这一调整是基于美国食品和药物管理局（FDA）最近宣布重新评估曾列入短缺清单的tirzepatide药物的可用性。 FDA在周五的一份法庭文件中表示，将重新考虑早前将tirzepatide从短缺清单中移除的决定。该机构还指出，在审查该活性成分的 ...
WKBW3 天
FDA is reconsidering its decision to take tirzepatide off its drug shortage list
Pharmacists can continue making compounded versions of generic tirzepatide, the active ingredient in popular medications ...
Drugmakers can keep making off-brand weight-loss drugs as FDA backpedals
Facing a lawsuit, the Food and Drug Administration has decided to reconsider its decision to take popular weight-loss and diabetes drugs off of the national shortage list, which will allow compounding ...